阿托伐他汀和瑞舒伐他汀对高海拔地区PCI患者血脂、炎症因子和血管内皮功能的影响(1)
摘要：目的 探讨阿托伐他汀和瑞舒伐他汀对高海拔地区经皮冠状动脉介入治疗(PCI)后患者血脂、炎症因子和血管内皮功能的影响。方法 选自青海大学附属医院心内科2015年4月～2016年4月的行PCI术的冠心病患者64例为研究对象。在给予相同基础药物治疗前提下，随机分组为阿托伐他汀组和瑞舒伐他汀组，每组32例。分别监测两组PCI前、PCI后3个月、PCI后6个月时间点总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、超敏C反应蛋白(Hs-CRP)、同型半胱氨酸(Hcy)、颈动脉内膜中层厚度(IMT)、肱动脉血流介导的血管内皮舒张功能(FMD)，分别比较两组在PCI前和PCI后3个月、6个月时TC、TG、HDL、LDL、Hs-CRP、Hcy、IMT、FMD的变化。结果 两组PCI前的TC、TG、HDL、LDL、Hs-CRP、Hcy、IMT、FMD比较，差异无统计学意义(P>0.05)。两组PCI后3个月、6个月时TC、TG、LDL、Hs-CRP、Hcy、IMT均较PCI前下降，且PCI后6个月较PCI后3个月下降更显著，瑞舒伐他汀组较阿托伐他汀组下降明显，差异有统计学意义(P<0.05)。两组PCI后3个月、6个月时HDL、FMD均较PCI前升高，且PCI后6个月较PCI后3月升高更显著，瑞舒伐他汀组较阿托伐他汀组升高明显，差异有统计学意义(P<0.05)。结论 阿托伐他汀和瑞舒伐他汀对高海拔地区PCI后患者的血脂有调节作用，还有抑制机体炎症反应和改善血管内皮功能的作用。瑞舒伐他汀比阿托伐他汀的效果更顯著。
, http://www.100md.com
关键词：瑞舒伐他汀;阿托伐他汀;高海拔;PCI;血脂;炎症因子;血管内皮功能
中图分类号：R541.4 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.06.022
文章编号：1006-1959(2019)06-0067-05
Abstract：Objective To investigate the effects of atorvastatin and rosuvastatin on serum lipids， inflammatory factors and vascular endothelial function in patients undergoing percutaneous coronary intervention (PCI) at high altitude. Methods A total of 64 patients with coronary heart disease who underwent PCI from April 2015 to April 2016 in Qinghai University Affiliated Hospital were included in the study. Under the premise of the same basic drug treatment， the patients were randomly divided into atorvastatin group and rosuvastatin group， 32 cases in each group.Total cholesterol (TC)， triglyceride (TG)， high-density lipoprotein (HDL)， low-density lipoprotein (LDL)， super-group were monitored before PCI， 3 months after PCI， and 6 months after PCI. Sensitive C-reactive protein (Hs-CRP)， homocysteine (Hcy)， carotid intima-media thickness (IMT)， and brachial artery blood flow-mediated vascular endothelial dilation function (FMD) were compared between the two groups in PCI. Changes in TC， TG， HDL， LDL， Hs-CRP， Hcy， IMT， and FMD at 3 months and 6 months after PCI. Results There were no significant differences in TC， TG， HDL， LDL， Hs-CRP， Hcy， IMT and FMD between the two groups before PCI (P>0.05).At 3 months and 6 months after PCI， TC， TG， LDL， Hs-CRP， Hcy and IMT were lower than those before PCI， and 6 months after PCI was more significant than 3 months after PCI. The statin group was significantly lower than the atorvastatin group，the difference was statistically significant (P<0.05). At 3 months and 6 months after PCI， HDL and FMD were higher than those before PCI， and 6 months after PCI was more significant than that after PCI. The rosuvastatin group was higher than the atorvastatin group，the difference was statistically significant (P<0.05). Conclusion Atorvastatin and rosuvastatin have a regulatory effect on blood lipids in patients with high altitude PCI， as well as inhibition of inflammatory response and improvement of vascular endothelial function. Rosuvastatin is more effective than atorvastatin., 百拇医药(沈有录 卢红涛 刘维军)
, http://www.100md.com
关键词：瑞舒伐他汀;阿托伐他汀;高海拔;PCI;血脂;炎症因子;血管内皮功能
中图分类号：R541.4 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.06.022
文章编号：1006-1959(2019)06-0067-05
Abstract：Objective To investigate the effects of atorvastatin and rosuvastatin on serum lipids， inflammatory factors and vascular endothelial function in patients undergoing percutaneous coronary intervention (PCI) at high altitude. Methods A total of 64 patients with coronary heart disease who underwent PCI from April 2015 to April 2016 in Qinghai University Affiliated Hospital were included in the study. Under the premise of the same basic drug treatment， the patients were randomly divided into atorvastatin group and rosuvastatin group， 32 cases in each group.Total cholesterol (TC)， triglyceride (TG)， high-density lipoprotein (HDL)， low-density lipoprotein (LDL)， super-group were monitored before PCI， 3 months after PCI， and 6 months after PCI. Sensitive C-reactive protein (Hs-CRP)， homocysteine (Hcy)， carotid intima-media thickness (IMT)， and brachial artery blood flow-mediated vascular endothelial dilation function (FMD) were compared between the two groups in PCI. Changes in TC， TG， HDL， LDL， Hs-CRP， Hcy， IMT， and FMD at 3 months and 6 months after PCI. Results There were no significant differences in TC， TG， HDL， LDL， Hs-CRP， Hcy， IMT and FMD between the two groups before PCI (P>0.05).At 3 months and 6 months after PCI， TC， TG， LDL， Hs-CRP， Hcy and IMT were lower than those before PCI， and 6 months after PCI was more significant than 3 months after PCI. The statin group was significantly lower than the atorvastatin group，the difference was statistically significant (P<0.05). At 3 months and 6 months after PCI， HDL and FMD were higher than those before PCI， and 6 months after PCI was more significant than that after PCI. The rosuvastatin group was higher than the atorvastatin group，the difference was statistically significant (P<0.05). Conclusion Atorvastatin and rosuvastatin have a regulatory effect on blood lipids in patients with high altitude PCI， as well as inhibition of inflammatory response and improvement of vascular endothelial function. Rosuvastatin is more effective than atorvastatin., 百拇医药(沈有录 卢红涛 刘维军)